Skip to content
Screener

NeoGenomics NEO Reportable Segment — NET LOSS

Similar metrics at other companies

Veradermics logo
MANEReportable Segment — Net loss
-$27.23M-120%
Zscaler logo
ZSReportable Segment — Net loss
-$13.88M-237%
Biohaven logo
BHVNReportable Segment — Net loss
-$130.53M+41.1%
Bicara Therapeutics logo
BCAXReportable Segment — Net loss
-$56.21M-52.6%
YSS
YSSReportable Segment — Net loss
-$114.84M-879%
Vaxcyte, Inc. logo
PCVXReportable Segment — Net loss
-$320.62M-128%

Other financials

Income statement

See full
Revenue$201.7M+11.2%
Gross profit$91.9M+18.9%
Operating income-$9.8M+79.5%
Net income$2.2M+105%
EPS (diluted)$0.02+106%

Balance sheet

See full
Cash & equivalents$145.5M-5.9%
Total debt$448.4M+534%
Total equity$785.7M-8.0%
Total assets$1.4B-3.0%

Cash flow

See full
Operating cash flow$20.0M-1.8%
CapEx$8.2M+30.0%
Free cash flow-$13.1M+56.0%

Valuation

See full
Market cap$2B+182%
Enterprise value$2.3B+268%
P/S2.6×+1.6×

Profitability

See full
Gross margin43.9%0.0pp
Operating margin-8.9%-2.8pp
Net margin-6.8%-2.4pp
FCF margin-4.9%

Returns & leverage

See full
Return on equity-6.3%-2.0pp
Debt / equity0.6×+0.5×
Current ratio3.6×-0.3×

Where this comes from

Reported directly by NeoGenomics in its filing.

Tagged under the XBRL concept us-gaap:NetIncomeLoss.

The source filing: NeoGenomics’s 10-Q, filed July 28, 2026.

Filed
Jul 28, 2026, 4:09 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001077183-26-000059
Line itemThree Months Ended June 30, 2026Three Months Ended June 30, 2025Six Months Ended June 30, 2026Six Months Ended June 30, 2025
Gain on extinguishment of debt (Note 6)11,18111,181
Income (loss) before taxes1,826(45,816)(15,752)(71,473)
Income tax benefit412724884458
NET INCOME (LOSS)$2,238$(45,092)$(14,868)$(71,015)
NET INCOME (LOSS) PER SHARE
Basic$0.02$(0.35)$(0.11)$(0.56)
Diluted$0.02$(0.35)$(0.11)$(0.56)
WEIGHTED AVERAGE COMMON SHARES OUTSTANDING

Item 1. Financial Statements (unaudited)

FAQ

What is NeoGenomics's reportable segment — NET LOSS?
NeoGenomics (NEO) reported reportable segment — NET LOSS of $2.24M in Q2 2026.
How has NeoGenomics's reportable segment — NET LOSS changed year-over-year?
NeoGenomics's reportable segment — NET LOSS increased by 105.0% year-over-year, from -$45.09M to $2.24M.
What is the long-term trend for NeoGenomics's reportable segment — NET LOSS?
Over 3 years (2022 to 2025), NeoGenomics's reportable segment — NET LOSS has grown at a -9.2% compound annual growth rate (CAGR), from -$144.25M to -$108.03M.
What does reportable segment — NET LOSS mean?
This is the final bottom-line financial result for the reportable segment after all operating expenses, interest, taxes, and non-operating items have been deducted. A net loss indicates that the segment's total costs exceeded its revenues for the reporting period.

Ask your AI about NeoGenomics's reportable segment — net loss.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude